Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We are now recruiting volunteers for Oxford Vaccine Group's new Ebola study: Evaluating Optimal Vaccine Schedules against Ebola (EVOLVE)

RECRUITING NOW!

You are invited to take part in a study investigating new vaccines against Ebola virus disease (EVD). The current outbreak of EVD in West Africa is estimated by the World Health Organization to have caused more than 10,000 deaths to date and is still ongoing. There is no specific treatment or cure for Ebola and an effective vaccine would be an important step in controlling the spread of disease. The study is being run by the Oxford Vaccine Group, part of the University of Oxford. 

►       If you are aged 18 to 65 years old and in good health you may be eligible to take part in the study

►       We will provide reimbursement for your time, inconvenience and travel

Interested individuals may attend a screening visit at our site to discuss this further and for their suitability for the study to be assessed.  If you would like to find out more, you can contact us via:

Ebolavaccine.org.uk

01865 857420

info@ovg.ox.ac.uk


This study is being run by the Oxford Vaccine Group, part of the University of Oxford and is funded by Crucell Holland BV.

Similar stories

Promising discovery for treatment of neuromuscular diseases

Research led by Carlo Rinaldi and Catheryn Lim discovered that a naturally-occurring isoform of an androgen receptor can be used in therapy for spinal and bulbar muscular atrophy, and shows potential for other diseases.

Vaccine for TB receives a $1.5 million funding boost

The Oxford-run VALIDATE Network has received $1.5 million in funding for its tuberculosis vaccine work from the Bill & Melinda Gates Foundation.

University of Oxford researchers among recipients of Ireland and UK joint research awards for digital humanities in €6.5m boost for interdisciplinary research partnerships

Dr Samantha Vanderslott (Oxford Vaccine Group) and Dr Claas Kirchhelle (University College Dublin) have had their three-year project ‘Typhoid, Cockles, and Terrorism’ about the history of typhoid in Dublin successfully funded.

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

Oxford Vaccine Group among winners at NHS Parliamentary awards

Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.